Marco Meglio

Ocrelizumab (Ocrevus; Genentech), an anti-CD20 treatment FDA-approved for progressive MS, was shown to reduce thalamic volume loss, with even greater outcomes when initiated earlier.

During months 36 and 48 on open-label cenobamate treatment, 76.4% and 51.8% of patients achieved seizure reductions of at least 50% or 75%, respectively.

In total, 100% and 93% of those in the SMN two- and three-copy cohorts achieved the primary end point of sitting independently for at least 30 seconds after 18 months of treatment.

Net improvement of 1 grade or more on Extended Glasgow Outcome Scale was observed in 30.4% of the surgical group compared with 14.5% of those on standard medical care.

BIIB122, a selective central nervous system-penetrant small molecule inhibitor of LRRK2 is expected to be evaluated in a cohort of 640 patients with early-stage Parkinson disease.

At least 2 weeks following Evusheld injection, all 18 patients included in the cohort had the highest level of antibody response.

The decision to stop clinical testing of SRP-5051 in DMD follows a serious adverse event of hypomagnesemia in part B of the phase 2 MOMENTUM trial.

Based on the 35-week interim trial results, AstraZeneca and Ionis will seek regulatory approval for eplontersen and plan to file a new drug application with the FDA in 2022.

After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.

Both the early- and delayed-start tofersen treatment groups demonstrated reductions in SOD1 protein, the intended target for tofersen, and neurofilament, a marker of axonal injury and neurodegeneration.

Originally approved for the preventive treatment of episodic migraine in Sept 2021, atogepant’s potential new indication stems from positive results from the double-blind, placebo-controlled, phase 3 PROGRESS trial.

Over an 18-month treatment period, patients with prodromal to mild Alzheimer disease demonstrated similar increases in Clinical Dementia Rating-Sum of Boxes scores regardless of treatment with placebo or semorinemab.

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the major talking points regarding sleep quality, sleep disorders, and late-life neurocognitive issues.

Endovascular therapy with alteplase was associated with lower morality, home discharge destination, greater likelihood to have no major disability, and ability to ambulate at discharge.

Through the StrivePD ecosystem and an Apple Watch, patients, including those who have been treated with Medtronics’ deep brain stimulation device, are able to track and log their symptoms.

After 24 weeks of treatment, the adjusted mean annualized relapse rates were 0.53 with placebo vs 0.39 and 0.48 for the 30- and 45-mg groups of IMU-838.

In the first NIH-backed study to evaluate an experimental prevention therapy in cognitively unimpaired persons at risk for Alzheimer disease, crenezumab showed small numerical, but not statistically significant differences compared with placebo.

The study, expected to be completed in 2024, will look specifically at vocal abnormalities related to the early stages of Parkinson disease progression.

On average, those with cluster headache had 4.8 cranial autonomic symptoms compared with 2.7 for those with migraine, regardless of aura status.

The agent will be evaluated in 2 pivotal trials of 225 patients requiring varying levels of assistance with daily living activities.

The graduate student at the University of Michigan provided insight on the ways to expand the current knowledge about the disparities among races and genders in sleep quality and long-term cognitive outcomes. [WATCH TIME: 3 minutes]

In the comparator study between ponesimod and teriflunomide, the risk of both 12- and 24-week confirmed disability accumulation at week 108 was significantly different between MAGNIMS score groups.

Meghan Garabedian, CRNP, MSN, nurse practitioner at the Penn Neuroscience Center, discussed her presentation at the 2022 CMSC Annual Meeting regarding the patient experience on diroximel fumarate.

Over a 24-week treatment period, 72.2% of those on erenumab achieved relevant improvement on HIT-6 scores compared with 53.9% of those on topiramate.

Galit L. Dunietz, PhD, MPH, assistant professor of neurology, University of Michigan, provided insight on women’s health, menopause cycles, and how sleep can have a direct impact on long-term cognitive health.

In the open-label extension where the highest dose of atogepant (Qulipta; AbbVie) was observed, 24.1% of participants had at least 7% weight loss compared with 14.7% of those on standard of care.

The associate neurologist at Brigham and Women’s Hospital discussed the potential of a nasal anti-CD3 monoclonal antibody, foralumab, and its impact on biomarkers specific to patients with progressive multiple sclerosis.

The approval was based on results from the phase 3 HELIOS-A study, which showed that vutrisiran met its primary end point of change in modified Neuropathy Impairment Score + 7 over a 9-month treatment period.

The most common adverse events reported by individuals using the dihydroergotamine nasal powder were nasal discomfort, dysgeusia, and nasal congestion, all of which were mild and transient in nature.

Secondary outcomes, assessed by the change in the number of monthly headache days by at least 25%, 75%, or 100%, were also not significant following treatment with CGRP monoclonal antibodies.